Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Leanne McCulloch"'
Autor:
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas
Publikováno v:
Breast, Vol 67, Iss , Pp 94-101 (2023)
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase
Externí odkaz:
https://doaj.org/article/59dce946fa4342e6b9fbbf464f2e5a40
Autor:
David Siegel, Thomas Martin, Ajay Nooka, R. Donald Harvey, Ravi Vij, Ruben Niesvizky, Ashraf Z. Badros, Sundar Jagannath, Leanne McCulloch, Kanya Rajangam, Sagar Lonial
Publikováno v:
Haematologica, Vol 98, Iss 11 (2013)
Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent carfilzomib have been analyzed for 526 patients with advanced multiple myeloma who took pa
Externí odkaz:
https://doaj.org/article/55177f5573994203a9589e2115fd7afe
Autor:
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, Adam Brufsky, Jo Chien, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A Cheong, Christian F Singer, Daniel Hunt, Navid Foruzan, Leanne McCulloch, Carlos H Barcenas
Publikováno v:
Cancer Research. 82:P5-18
Background: Neratinib (NERLYNX®), an irreversible pan-HER tyrosine kinase inhibitor, is approved for the extended adjuvant treatment of early-stage HER2+ breast cancer following adjuvant trastuzumab-based therapy and in combination with capecitabine
Autor:
Ron Bose, Maureen E. Trudeau, José A. García-Sáenz, Adam Brufsky, Arlene Chan, Gavin Marx, Debu Tripathy, M. Thirlwell, Daniel Hunt, Utpal Khambholja, Manuel Ruiz-Borrego, Naisargee Shah, Carlos H. Barcenas, A. Jo Chien, Leanne McCulloch, Daniel Egle
Publikováno v:
Cancer Research. 81:PS13-20
Background: Neratinib (NERLYNX®), an irreversible pan-HER tyrosine kinase inhibitor, is used for the extended adjuvant treatment of patients with early-stage HER2-positive (HER2+) breast cancer following adjuvant trastuzumab-based therapy and for pa
Autor:
Leanne McCulloch, Sara A. Hurvitz, Manuel Ruiz-Borrego, A. Jo Chien, Arlene Chan, Debu Tripathy, Daniel Hunt, Gavin Marx, Carlos H. Barcenas, Cynthia Farrell
Publikováno v:
Cancer Research. 80:P5-14
Background: Neratinib (NERLYNX®), an irreversible pan-HER tyrosine kinase inhibitor, is used for the extended adjuvant treatment of patients with early-stage HER2-positive (HER2+) breast cancer following adjuvant trastuzumab-based therapy. Diarrhea
Autor:
Michael K. Guy, Alshad S. Lalani, James Bolognese, Andre Teixeira, Pravin Chaturvedi, Irmina Diala, Leanne McCulloch
Publikováno v:
Cancer Research. 80:580-580
Crofelemer is a novel allosteric modulator of cystic fibrosis transmembrane conductance regulator (CFTR) that is approved as an antidiarrheal in HIV patients receiving antiretroviral therapy. Neratinib is an oral, irreversible pan-HER tyrosine kinase
Autor:
Cindy Farrell, Carlos H. Barcenas, Ron Bose, Hope S. Rugo, Sara A. Hurvitz, Jack A. Di Palma, Leanne McCulloch, Debu Tripathy, Daniel Hunt, Amy Kupic, Amy Jo Chien, Arlene Chan
Publikováno v:
Journal of Clinical Oncology. 37:548-548
548 Background: CONTROL (clinicaltrials.gov: NCT02400476) is an open-label, sequential-cohort, phase II study investigating the effectiveness of prophylaxis or dose escalation in preventing diarrhea and improving tolerability of neratinib, an irrever
Autor:
Julien Mazieres, Benjamin Besse, David S. Ettinger, Leanne Mcculloch, Kathryn A. Gold, Mark A. Socinski, Leora Horn, Gregory A. Otterson, Fabrice Barlesi, Alexis B. Cortot, Daniel B. Costa, Leena Gandhi, Ana B. Oton, Saiama N. Waqar, Rebecca S. Heist, Richard A. Bryce, Jhanelle E. Gray, Denis Moro-Sibilot, Mark G. Kris, Judith Bebchuk, Elisabeth Quoix
Publikováno v:
Journal of Thoracic Oncology. 12:S358-S359
Autor:
Ravi Vij, Ashraf Badros, Ruben Niesvizky, David S. Siegel, Ajay K. Nooka, Leanne McCulloch, Sagar Lonial, R. Donald Harvey, Sundar Jagannath, Kanya Rajangam, Thomas Martin
Publikováno v:
Haematologica. 98(11)
Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent carfilzomib have been analyzed for 526 patients with advanced multiple myeloma who took pa
Publikováno v:
Blood. 120:4037-4037
Abstract 4037 Background: Cardiac and pulmonary events are common comorbidities in patients (pts) with multiple myeloma (MM) that typically affect older adults (Robin J, et al. J Med Case Rep. 2008) and are aggravated by chronic anemia and cardiotoxi